Trends in Endocrinology & Metabolism
ReviewNuclear receptors as drug targets in metabolic diseases: new approaches to therapy
Introduction
Nuclear receptors represent one of the largest families of transcription factors, with 48 present in the human genome. These receptors are activated through the binding of hydrophobic ligands, including fatty acids (FAs), hormones, bile acids and oxysterols. Nuclear receptors are modular in nature. They contain an amino-terminal ligand-independent activation function 1 transactivation domain, a DNA-binding domain containing two zinc finger motifs and a carboxy-terminal domain that contains a dimerization domain and a ligand-dependent activation function 2 transactivation domain [1]. Some nuclear receptors can bind DNA and activate transcription of their target genes as monomers but the majority of these receptors are active as homodimers or heterodimers bound to the retinoid X receptor. In the absence of a ligand, nuclear receptors form complexes with corepressors such as the nuclear receptor corepressor and the silencing mediator for retinoic acid receptor and thyroid hormone receptor 2, 3, 4, which repress transcription through the recruitment of histone deacetylases. Ligand binding induces a conformational change that results in the dissociation of corepressors and the recruitment of coactivators, such as peroxisome proliferator-activated receptor coactivator 1 and the cAMP response element-binding protein-binding protein–p300 5, 6, 7. The specificity of the complexes formed between the receptor and corepressors or coactivators appears to be determined by the cell type, the conformational change induced by the ligand and the sequence of the DNA-binding element. This level of complexity enables fine-tuning of the physiological response and explains the variability of gene expression changes when a receptor is activated by different ligands 8, 9.
The metabolism of glucose, fat, cholesterol and bile acids is controlled, in part, by a subset of nuclear receptors. In this review we focus on the function of the peroxisome proliferator-activated receptors (PPARs) [10], the liver X receptors (LXRs) and the farnesoid X receptor (FXR) [11] in human diseases, including type 2 diabetes, dyslipidemia, atherosclerosis and the metabolic syndrome (Table 1).
Section snippets
PPARs
There are three members of the PPAR family: PPAR-α, PPAR-γ, and PPAR-δ [10]. They are 60–80% conserved in their DNA- and ligand-binding domains and are activated by several natural and synthetic ligands, including eicosanoids, free fatty acids (FFAs), lipid-lowering drugs (the fibrates) and the insulin-sensitizing agents thiazolidinediones (TZDs).
LXRs
Two isoforms of LXR exist, and they function as intracellular sensors of oxysterol levels [11]. Expression is highest in the liver and intestine but LXR-α is also detected in macrophages, adipose tissue, kidney, lung and spleen, whereas LXR-β is ubiquitously expressed. The role of LXR in the enterohepatic system and in macrophages is best studied, and is discussed below [11].
LXRs are involved in cholesterol homeostasis. Mice deficient in LXR-α develop hepatomegaly and accumulate large
FXR
Similarly to the LXRs, FXR is highly expressed in the liver and intestine, and serves as a bile acid sensor [11]. Its natural ligands are bile acids, including cholic acid and chenodeoxycholic acid. Conversion of cholesterol to bile acids is the major pathway for elimination of cholesterol [66]. Bile acids are important for the digestion and absorption of lipids, fat-soluble vitamins and cholesterol from the intestinal tract. Ninety-five percent of secreted bile acids are reabsorbed by
Summary
Despite recent therapeutic advances, the prevalence of type 2 diabetes, insulin resistance and the metabolic syndrome has risen to epidemic proportions. Oral antidiabetic agents are moderately effective but their efficacy in controlling hyperglycemia is limited by dose-related tolerability, most notably weight gain. PPAR-γ partial agonists, PPAR-α and -γ dual agonists, PPAR-δ agonists and pan-agonists are currently being evaluated in clinical trials, and offer significant advantages relating to
Acknowledgements
We thank Dave Erbe, Vipin Suri and George Vlasuk for comments on the manuscript.
References (96)
The nuclear receptor superfamily: the second decade
Cell
(1995)p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively
J. Biol. Chem.
(1999)Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma
J. Biol. Chem.
(1999)Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
J. Biol. Chem.
(1997)- et al.
PPAR signaling in the control of cardiac energy metabolism
Trends Cardiovasc. Med.
(2000) Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Pharmacol. Ther.
(2002)- et al.
Atherosclerosis. the road ahead
Cell
(2001) Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein
J. Biol. Chem.
(2003)- et al.
Adipose tissue as an active endocrine organ: recent advances
Curr. Opin. Pharmacol.
(2005) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
J. Biol. Chem.
(2003)